Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Recurrent ganglioglioma in adults treated with BRAF inhibitors.

CNS oncology - 1 Jan 2016

Chamberlain Marc C

Abstract excerpt

Thirteen adult patients with temozolomide, surgery and radiation refractory ganglioglioma were screened for the BRAF V600E mutation. Three (23%) were found positive for the presence of the BRAF mutation and were treated with the BRAF inhibitor dabrafenib. Dabrafenib was well tolerated with no grade 3 or higher toxicity. The median number of cycles was 7 (a cycle was defined as 1 month of daily dabrafenib) and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Enzyme Inhibitors
Share to Ganglioglioma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glutamic Acid

Share to Imidazoles

Share to Oximes

Share to Proto-Oncogene Proteins B-raf

Share to Valine

Source

Open in PubMed Open full text

Identifiers

PMID: 26680369
DOI: 10.2217/cns.15.40
PMCID: PMC6078155

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Recurrent ganglioglioma in adults treated with BRAF inhibitors.PMID 26680369Read ↗

Clinical response to dabrafenib plus trametinib in a pediatric ganglioglioma with BRAF p.T599dup mutation.Semantic proximity Read ↗

BRAF inhibition efficacy in drug-refractory epilepsySemantic proximity Read ↗

Sustained Tumor Control With MAPK Inhibition in BRAF V600–Mutant Adult Glial and Glioneuronal TumorsSemantic proximity Read ↗

Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease.Semantic proximity Read ↗

Combination of BRAF and MEK inhibition in BRAF V600E mutant low-grade ganglioglioma.Semantic proximity Read ↗

Dabrafenib Treatment in a Patient with an Epithelioid Glioblastoma and BRAF V600E Mutation.Semantic proximity Read ↗

Personalized Treatment for a Patient With a BRAF V600E Mutation Using Dabrafenib and a Tumor Treatment Fields Device in a High-Grade Glioma Arising From Ganglioglioma.Semantic proximity Read ↗

Ganglioglioma with MAP2K1 Mutation and CDKN2A/B Homozygous Deletion: A Case Report.Semantic proximity Read ↗

Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib.Semantic proximity Read ↗

Dabrafenib and trametinib in BRAFV600E mutated glioma.Semantic proximity Read ↗

Rapid symptomatic improvement in two patients with ganglioglioma after restarting BRAF inhibitor therapy.Semantic proximity Read ↗

Vemurafenib and cobimetinib overcome resistance to vemurafenib in BRAF-mutant ganglioglioma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.